| Abuse of growth hormone increases the risk of persistent de Quervain tenosynovitis. | |
| | |
MedLine Citation:
|
PMID: 19797164 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: de Quervain tenosynovitis usually responds well to nonsurgical treatment. HYPOTHESIS: Growth hormone abuse is associated with increased de Quervain tenosynovitis incidence in weight-training persons. STUDY DESIGN: Cohort study; Level of evidence, 3. METHODS: We treated 19 weight-training male patients with de Quervain tenosynovitis. Nine were abusing growth hormone (group A), and 10 were not (group B). Four group A patients elected to cease growth hormone abuse. Treatment was stratified into 3 grades: (1) splinting and nonsteroidal anti-inflammatory drugs, (2) same as first grade but with the addition of cortisone injections, and (3) surgical decompression (after failure of treatment of first and second grades). Follow-up was at 3, 9, and 24 months. RESULTS: First follow-up: Only 33.3% of those using growth hormone in group A responded to splinting and nonsteroidal anti-inflammatory drugs, compared with 90% in group B. Six patients (66.6%) in group A experienced persistent symptoms and received second-grade treatment, compared with 1 patient in group B (10%). Second follow-up: Four patients (44.4%) in group A moved from second- to third-grade treatment, 1 symptom-free patient (11.1%) relapsed and received second-grade treatment while 2 (22.2%) requested conservative treatment, declining surgery. Group B patients were 100% symptom-free. Final follow-up: Six patients (66.6%) in group A were operated on and 1 (11.1%) suffered from persistent de Quervain tenosynovitis, declining surgery. In group B, 1 patient relapsed and was started on second-grade treatment. No patients in group B had surgery. CONCLUSION: Our results suggest that growth hormone abuse is associated with a more recalcitrant form of de Quervain tenosynovitis that does not respond well to nonsurgical treatment, thus leading to increased likelihood of surgical decompression. |
| | |
Authors:
|
Thomas Pagonis; Konstantinos Ditsios; Panagiotis Givissis; Athanasios Pagonis; Anastasios Christodoulou |
Related Documents
:
|
23147434 - Predictors of mortality in patients undergoing percutaneous aortic valve implantation. 15373864 - Conservative management of vestibular schwannomas - second review of a prospective long... 21576994 - A comparison of jurkat cell-reactive anti-t lymphocyte globulin and fetal anti-thymocyt... 23159134 - Impact of serum c-reactive protein measurements in the first 2 days on the 30-day morta... 23134554 - Endoscopic treatment for biliary stricture after orthotopic liver transplantation: succ... 18402394 - Primary non-refluxing megaureter: need for conservative treatment. |
Publication Detail:
|
Type: Journal Article Date: 2009-09-24 |
Journal Detail:
|
Title: The American journal of sports medicine Volume: 37 ISSN: 1552-3365 ISO Abbreviation: Am J Sports Med Publication Date: 2009 Nov |
Date Detail:
|
Created Date: 2009-10-30 Completed Date: 2010-01-15 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7609541 Medline TA: Am J Sports Med Country: United States |
Other Details:
|
Languages: eng Pagination: 2228-33 Citation Subset: IM |
Affiliation:
|
First Orthopaedic Clinic of Aristotle University of Thessaloniki, General University Hospital of George Papanikolaou, Thessaloniki, Greece. 6972550911@mycosmos.gr |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Case-Control Studies Cohort Studies De Quervain Disease / chemically induced*, surgery Decompression, Surgical Growth Hormone / adverse effects* Humans Male Resistance Training / adverse effects Substance-Related Disorders* Treatment Failure Young Adult |
| Chemical | |
Reg. No./Substance:
|
9002-72-6/Growth Hormone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Biomechanical evaluation of 2 arthroscopic biceps tenodeses: double-anchor versus percutaneous intra...
Next Document: The von Hippel Lindau tumor suppressor limits longevity.